Why Tempus AI Stock Is Skyrocketing Today

Source The Motley Fool

Shares of Tempus AI (NASDAQ: TEM) were skyrocketing 16.5% higher as of 10:39 a.m. ET on Wednesday. The big gain came after the healthcare artificial intelligence (AI) company announced a multiyear partnership with AstraZeneca and Pathos AI to build a multimodal foundation model for cancer drug discovery and development.

Tempus AI has invested heavily over the last decade to create one of the world's largest libraries of multimodal data that can be used in developing precision medicines. The company's de-identified oncology data will be critical in building the foundation model that AstraZeneca hopes to use to accelerate its development of new cancer drugs and increase the chances of success in clinical testing for its candidates.

Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More »

What this deal means for Tempus AI

Tempus AI will receive $200 million in data licensing and model development fees from AstraZeneca. This amount almost exactly matches the amount of revenue the company generated in the fourth quarter of 2024.

The healthcare AI company will also be able to use the multimodal foundation model it's building in collaboration with AstraZeneca and Pathos AI in its own efforts to improve patient care. This could bode well for Tempus AI's appeal to other big drugmakers seeking to harness the power of AI in their drug development processes.

Is Tempus AI stock a smart pick to buy now?

Risk-averse investors probably should look to other stocks to buy instead of Tempus AI. The company continues to lose money and is difficult to value. However, I think Tempus AI could be a smart pick for aggressive growth investors to buy and hold. The deal with AstraZeneca underscores the promise of its AI platform and data.

Should you invest $1,000 in Tempus Ai right now?

Before you buy stock in Tempus Ai, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Tempus Ai wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $561,046!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $606,106!*

Now, it’s worth noting Stock Advisor’s total average return is 811% — a market-crushing outperformance compared to 153% for the S&P 500. Don’t miss out on the latest top 10 list, available when you join Stock Advisor.

See the 10 stocks »

*Stock Advisor returns as of April 21, 2025

Keith Speights has no position in any of the stocks mentioned. The Motley Fool recommends AstraZeneca Plc. The Motley Fool has a disclosure policy.

Disclaimer: For information purposes only. Past performance is not indicative of future results.
placeholder
Gold Price Forecast: XAU/USD declines below $4,050 on USD strength and hawkish Fed comments Gold price (XAU/USD) extends the decline to around $4,030 during the early Asian session on Tuesday. The precious metal edges lower as traders dialed back expectations of a US interest rate cut next month.
Author  FXStreet
Nov 18, Tue
Gold price (XAU/USD) extends the decline to around $4,030 during the early Asian session on Tuesday. The precious metal edges lower as traders dialed back expectations of a US interest rate cut next month.
placeholder
Top 3 Price Prediction: Bitcoin, Ethereum, Ripple – BTC, ETH and XRP Look for a Foothold After a Sharp ShakeoutBitcoin trades near $92,600 after a dip below $90,000, while Ethereum around $3,118 and XRP near $2.21–$2.23 sit on key support zones, as BTC, ETH and XRP all try to turn a sharp correction into a tradable rebound rather than a deeper slide.
Author  Mitrade
Nov 19, Wed
Bitcoin trades near $92,600 after a dip below $90,000, while Ethereum around $3,118 and XRP near $2.21–$2.23 sit on key support zones, as BTC, ETH and XRP all try to turn a sharp correction into a tradable rebound rather than a deeper slide.
placeholder
Could XRP Really Catch Ethereum? Analysts Revisit the Question as ETF Tailwinds BuildAs US spot XRP ETFs roll out and issuers like Canary Capital and Franklin Templeton step in, analysts say XRP’s market cap could climb on growing utility and ETF accumulation—but overtaking Ethereum’s $373 billion smart-contract powerhouse remains a long-shot, at least for now.
Author  Mitrade
Nov 20, Thu
As US spot XRP ETFs roll out and issuers like Canary Capital and Franklin Templeton step in, analysts say XRP’s market cap could climb on growing utility and ETF accumulation—but overtaking Ethereum’s $373 billion smart-contract powerhouse remains a long-shot, at least for now.
placeholder
Bitcoin's Drop to $86K Approaches 'Max Pain' Zone, Yet Presents Potential Buying OpportunityAnalysts identify the $84,000 to $73,000 range as Bitcoin's likely "max pain" territory where capitulation may occur.
Author  Mitrade
Nov 21, Fri
Analysts identify the $84,000 to $73,000 range as Bitcoin's likely "max pain" territory where capitulation may occur.
placeholder
Market Meltdown: BTC, ETH, and XRP Capitulate as Bears Seize ControlBitcoin trades around $85,900 after breaking below $86,000, with Ethereum under $2,791 and XRP below $1.99 as BTC, ETH and XRP extend weekly losses of 8–10%, forcing traders to focus on supports at $85,000, $2,749 and $1.77 for clues on whether this sell-off has further to run.
Author  Mitrade
Nov 21, Fri
Bitcoin trades around $85,900 after breaking below $86,000, with Ethereum under $2,791 and XRP below $1.99 as BTC, ETH and XRP extend weekly losses of 8–10%, forcing traders to focus on supports at $85,000, $2,749 and $1.77 for clues on whether this sell-off has further to run.
goTop
quote